- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024
Acumen’s sabirnetug is the first humanized monoclonal antibody to clinically demonstrate target engagement of AβOs, a soluble and highly toxic form of Aβ that accumulates early in AD and triggers synaptic dysfunction and neurodegeneration.
Acumen’s presentation will include deeper insights into the safety, target engagement and biomarker findings from INTERCEPT-AD. Presentation details are as follows:
- Platform Presentation: 007 - A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and biomarker changes,
6:06 PM –6:12 PM MDT - Poster Q&A:
6:25 PM –7:00 PM MDT - Presenting Author:
Eric Siemers , M.D., Chief Medical Officer,Acumen Pharmaceuticals - Topic: Aging, Dementia, Cognitive, and Behavioral Neurology
- Platform Session and Poster Q&A Date & Time:
Tuesday, April 16 ,5:30 PM –7:00 PM MDT
“There’s been tremendous progress in the field of Alzheimer’s disease over the last few years and a particular interest in the use of biomarkers for a variety of neurological conditions,” said Daniel O’Connell, President and Chief Executive Officer of
About Sabirnetug (ACU193)
Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble AβOs, which are a highly toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, sabirnetug aims to directly address a growing body of evidence indicating that soluble AβOs are a primary underlying cause of the neurodegenerative process in Alzheimer’s disease. Sabirnetug has been granted Fast Track designation for the treatment of early Alzheimer’s disease by the
About INTERCEPT-AD
INTERCEPT-AD was a Phase 1,
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “potential,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning the therapeutic potential of Acumen’s product candidate, sabirnetug (ACU193), Acumen’s preparations with respect to its plans to initiate a Phase 2 study. These statements are based upon the current beliefs and expectations of Acumen’s management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen’s programs are described in additional detail in Acumen’s filings with the
Investors:
abraun@acumenpharm.com
Media:
ICR Westwicke
AcumenPR@westwicke.com
Source:
2024 GlobeNewswire, Inc., source